Clinical Trial Update: Safety and Dose Study of GRN163L and Velcade to Treat Patients With Refractory or Relapsed Myeloma [Phase 1]

View source ↗

Summary

Phase 1 safety and dose study of GRN163L with Velcade (bortezomib) in patients with refractory or relapsed multiple myeloma has completed. The study explored to…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• GRN163L (imetelstat)
• Velcade (bortezomib)

Snippet

Sponsor: Geron Corporation | Conditions: Multiple Myeloma | Phase 1 | Status: COMPLETED